Iron chelation for the treatment of uveitis

Junru Chen; Juan Zhou; Mel Kelly; Bruce E Holbein; Christian Lehmann

doi:10.1016/j.mehy.2017.03.029

Iron chelation for the treatment of uveitis

Med Hypotheses. 2017 Jun:103:1-4. doi: 10.1016/j.mehy.2017.03.029. Epub 2017 Mar 30.

Authors

Junru Chen¹, Juan Zhou², Mel Kelly³, Bruce E Holbein⁴, Christian Lehmann⁵

Affiliations

¹ West China School of Medicine, Sichuan University, Chengdu, China.
² Department of Microbiology and Immunology, Dalhousie University, Halifax, Canada; Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, Canada.
³ Department of Pharmacology, Dalhousie University, Halifax, Canada.
⁴ Chelation Partners Inc, Canada.
⁵ Department of Microbiology and Immunology, Dalhousie University, Halifax, Canada; Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, Canada; Department of Pharmacology, Dalhousie University, Halifax, Canada; Department of Physiology and Biophysics, Dalhousie University, Halifax, Canada. Electronic address: chlehmann@dal.ca.

PMID: 28571790
DOI: 10.1016/j.mehy.2017.03.029

Abstract

Inflammatory eye diseases such as uveitis are common and may eventually result in vision loss. Iron can play a critical role in ocular inflammation via promoting the generation of oxygen free radicals and it is also nutritionally essential for microbial growth. Considering this involvement of iron in inflammation and microbial infection, we hypothesize that administration of iron chelators has potential to function as a novel therapy in uveitis and help improve clinical outcomes.

MeSH terms

Animals
Free Radicals
Homeostasis
Humans
Inflammation
Iron / adverse effects
Iron Chelating Agents / therapeutic use*
Models, Theoretical
Reactive Oxygen Species / metabolism
Treatment Outcome
Uveitis / drug therapy*
Vision Disorders / drug therapy*

Substances

Free Radicals
Iron Chelating Agents
Reactive Oxygen Species
Iron